1-2 of 2
Marek Dziegielewski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy

Bartlomiej Borek, Julita Nowicka, Anna Gzik, Marek Dziegielewski, Karol Jedrzejczak, Joanna Brzezinska, Marcin Grzybowski, Paulina Stanczak, Paulina Pomper, Agnieszka Zagozdzon, Tomasz Rejczak, Krzysztof Matyszewski, Adam Golebiowski, Jacek Olczak, Kamil Lisiecki, Magdalena Tyszkiewicz, Magdalena Kania, Sylwia Piasecka, Anna Cabaj, Paulina Dera, Krzysztof Mulewski, Jacek Chrzanowski, Damian Kusmirek, Elzbieta Sobolewska, Marta Magdycz, Lukasz Mucha, Marek Masnyk, Jakub Golab, Marcin Nowotny, Elzbieta Nowak, Agnieszka Napiorkowska-Gromadzka, Stanislaw Pikul, Radoslaw Jazwiec, Karolina Dzwonek, Pawel Dobrzanski, Michael Meyring, Krzysztof Skowronek, Piotr Iwanowski, Zbigniew Zaslona, Roman Blaszczyk
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (7): 807–817.
https://doi.org/10.1158/1535-7163.MCT-22-0721
Published: 05 July 2023
View article titled, Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Open the PDF for Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Abstract B003: Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy

Paulina Seweryna Stanczak, Marcin Mikolaj Grzybowski, Paulina Wolska, Anna Maria Zdziarska, Marcin Mazurkiewicz, Paulina Pilanc, Anna Gieryng, Bozena Kaminska, Anna Gzik, Marek Dziegielewski, Karol Jedrzejczak, Bartlomiej Borek, Roman Blaszczyk, Adam Golebiowski, Pawel Dobrzanski, Karolina Dzwonek
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B003.
https://doi.org/10.1158/1535-7163.TARG-17-B003
Published: 01 January 2018
View article titled, Abstract B003: Development of OAT-1746, a novel arginase 1 and 2 inhibitor for cancer immunotherapy